Not yet recruiting NCT07331792
Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Topical 1 % clotrimazole twice daily 2 weeks, Oral itraconazole 200mg daily for 5 days.
- Who it may be relevant to
- Registry conditions: Pityriasis Versicolor. Basic parameters: 15 years — 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Comparative efficacy of topical 1% clotrimazole vs oral itraconazole in the treatment of pityriasis versicolor -Randomized control trial
Interventions
- Drug Topical 1 % clotrimazole twice daily 2 weeks
Topical 1% clotrimazole twice daily for 2 weeks - Drug Oral itraconazole 200mg daily for 5 days
Oral itraconazole 200mg daily for 5 days
Primary outcome measures
- Percentile efficacy of topical versus oral antifungal in the treatment of pityriasis versicolor [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Age (15-50 years)
- Both genders
- Sufferers of Pityriasis versicolor ( Determined by scale , erythema and pruritus)
Exclusion criteria
- Pt with history of antifungals in last one month
- Pt on immunosuppressants or steroid therapy
- Pregnant and lactating women
- Pt with chronic medical conditions ( Diabetes and hypertension)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Bamford JTM, Flores-GenuinoRNS, Ray S, Bigby M, Morales-Sánchez MA, Arkoncel M, et al. Interventions for the treatment of pityriasis versicolor. Cochrane Database Syst Rev. 2018;2018(6):CD011208. https://doi.org/10.1002/14651858.CD011208.pub2
- Hill RC, Faria W, Gold JAW, Lipner SR. Factors associated with pityriasis versicolor in a large national database. Mycoses. 2024 Aug;67(8):e13775. doi: 10.1111/myc.13775. PMID 39079943
- Kurniadi I, Hendra Wijaya W, Timotius KH. Malassezia virulence factors and their role in dermatological disorders. Acta Dermatovenerol Alp Pannonica Adriat. 2022 Jun;31(2):65-70. PMID 35751534
- Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Tinea versicolor: an updated review. Drugs Context. 2022 Nov 14;11:2022-9-2. doi: 10.7573/dic.2022-9-2. eCollection 2022. PMID 36452877
- Labedz N, Navarrete-Dechent C, Kubisiak-Rzepczyk H, Bowszyc-Dmochowska M, Pogorzelska-Antkowiak A, Pietkiewicz P. Pityriasis Versicolor-A Narrative Review on the Diagnosis and Management. Life (Basel). 2023 Oct 22;13(10):2097. doi: 10.3390/life13102097. PMID 37895478
Identifiers
NCT: NCT07331792 · CMH-Atd-ETH-200-Derm-25